Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
C4-MOSART trial: what clinicians have said so far
Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer
- NCT03431948 ↗
- Completed
- University of Chicago
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on C4-MOSART yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on C4-MOSART so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- Platform Phase 1 Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Immuno-oncology Agents for the Treatment of Multiple Metastases in Advanced Solid Tumors
- Phase
- Phase 1
- Status
- Completed
- Conditions
- Cancer
- Interventions
- Nivolumab; Cabiralizumab; Urelumab; Stereotactic Body Radiation Therapy
- Arms
- SBRT with Nivolumab and Urelumab · Experimental
- SBRT with Nivolumab and Cabiralizumab · Experimental
- Enrollment
- 60
- Primary outcomes
- Recommended dose of SBRT given in combination with immunotherapy
- Sponsor
- University of Chicago with Bristol-Myers Squibb
- Start
- Mar 15, 2018
- Primary completion
- Feb 29, 2020
- Results posted
- No
- Registry record
- NCT03431948 · updated Feb 16, 2023